Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165464 · ClinicalTrials.gov registry record · Phase 2
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT00165464 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 54 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT00165464, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Irinotecan
- DRUG Taxotere
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Faulkner Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165464
The ClinicalTrials.gov registry entry for NCT00165464 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT00165464 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165464 about?
NCT00165464 is a clinical study titled "Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer". This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
What is the current status of trial NCT00165464?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-08. Estimated completion is 2009-04.
What conditions does trial NCT00165464 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, GE Junction Cancer.
What interventions are being tested in trial NCT00165464?
The interventions under investigation include: Cisplatin (DRUG), Irinotecan (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00165464?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165464 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.